<code id='3738BB4BCB'></code><style id='3738BB4BCB'></style>
    • <acronym id='3738BB4BCB'></acronym>
      <center id='3738BB4BCB'><center id='3738BB4BCB'><tfoot id='3738BB4BCB'></tfoot></center><abbr id='3738BB4BCB'><dir id='3738BB4BCB'><tfoot id='3738BB4BCB'></tfoot><noframes id='3738BB4BCB'>

    • <optgroup id='3738BB4BCB'><strike id='3738BB4BCB'><sup id='3738BB4BCB'></sup></strike><code id='3738BB4BCB'></code></optgroup>
        1. <b id='3738BB4BCB'><label id='3738BB4BCB'><select id='3738BB4BCB'><dt id='3738BB4BCB'><span id='3738BB4BCB'></span></dt></select></label></b><u id='3738BB4BCB'></u>
          <i id='3738BB4BCB'><strike id='3738BB4BCB'><tt id='3738BB4BCB'><pre id='3738BB4BCB'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:fashion    - browse:67536

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge